Achmea Investment Management B.V. Sells 7,778 Shares of Edwards Lifesciences Co. (NYSE:EW)

Achmea Investment Management B.V. decreased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 15.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,612 shares of the medical research company's stock after selling 7,778 shares during the quarter. Achmea Investment Management B.V.'s holdings in Edwards Lifesciences were worth $3,154,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $30,000. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the third quarter valued at about $30,000. Prospera Private Wealth LLC purchased a new stake in shares of Edwards Lifesciences in the third quarter worth about $32,000. Avior Wealth Management LLC boosted its position in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after acquiring an additional 308 shares during the period. Finally, Roble Belko & Company Inc purchased a new position in Edwards Lifesciences during the fourth quarter valued at approximately $46,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Trading Up 0.7 %

EW traded up $0.53 during midday trading on Wednesday, reaching $70.87. 5,201,385 shares of the company's stock traded hands, compared to its average volume of 4,590,816. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a fifty day moving average of $71.61 and a two-hundred day moving average of $70.35. The stock has a market capitalization of $41.66 billion, a price-to-earnings ratio of 10.17, a P/E/G ratio of 4.82 and a beta of 1.12.

Remove Ads

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares of the company's stock, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the company's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,189,770.56. This trade represents a 16.83 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 51,303 shares of company stock worth $3,715,776. Corporate insiders own 1.29% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Piper Sandler raised their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Barclays lifted their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Stifel Nicolaus upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their target price for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. The Goldman Sachs Group lifted their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the company a "buy" rating in a research report on Thursday, December 5th. Finally, Morgan Stanley upped their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.